MediciNova (NASDAQ:MNOV – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare MediciNova to related businesses based on the strength of its earnings, analyst recommendations, dividends, valuation, profitability, risk and institutional ownership.
Profitability
This table compares MediciNova and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediciNova | -1,126.60% | -26.47% | -24.24% |
| MediciNova Competitors | -2,391.71% | -204.89% | -14.89% |
Institutional and Insider Ownership
9.9% of MediciNova shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.0% of MediciNova shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares MediciNova and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| MediciNova | $935,717.00 | -$12.00 million | -6.24 |
| MediciNova Competitors | $18.73 billion | $3.24 billion | 560.54 |
MediciNova’s peers have higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
MediciNova has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, MediciNova’s peers have a beta of -0.05, indicating that their average share price is 105% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for MediciNova and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediciNova | 1 | 1 | 4 | 1 | 2.71 |
| MediciNova Competitors | 7870 | 13817 | 25857 | 1043 | 2.41 |
MediciNova currently has a consensus target price of $7.75, suggesting a potential upside of 491.60%. As a group, “Pharmaceuticals” companies have a potential upside of 30.30%. Given MediciNova’s stronger consensus rating and higher probable upside, research analysts clearly believe MediciNova is more favorable than its peers.
Summary
MediciNova beats its peers on 7 of the 13 factors compared.
MediciNova Company Profile
MediciNova is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries. Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders.
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.
